Merck

Kintayl Capital Adds $7.6M Stake in NorthWestern Energy Group, Highlighting Utility's Strong Outlook

Halozyme Therapeutics

Healthcare Stocks Tumble Amid Rate-Sensitive Sector Rotation

Halozyme Secures Preliminary Injunction Against Merck & Co. in Keytruda Patent Dispute

默沙东

Merck: Scotiabank raises PT to $120 from $105, maintains Sector Outperform rating.

Merck's 15-minute chart shows MACD Death Cross, KDJ Death Cross signals.

Catalyst<ul> <li>Most analysts rate MRK Buy or Strong Buy, showing broad institutional optimism.</li> <li>Recent Bullish bias from RSI Overbought and Marubozu White signals in late November and early December point to potential upward momentum for MRK.</li></ul>Risk<ul> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li> <li>Fund flow trends show net outflows in Medium and Large orders, indicating reduced institutional confidence.</li> <li>New FDA leadership could raise the bar for drug approvals, increasing regulatory uncertainty for pharmaceutical companies like MRK.</li></ul>

Key Factors

Halozyme secured a preliminary injunction against Merck in Germany over Keytruda SC patent infringement.Scotiabank raised Merck's price target to $120 from $105 and maintained a Sector Outperform rating.Goldman Sachs raised Merck's price target to $120 and maintained a Buy rating.Merck's CADENCE trial results showed positive outcomes but fell short of FDA submission criteria.Merck was named a Top Socially Responsible Dividend Stock with a 3.3% yield and ESG recognition.

Recent Updates

MRK News